2019 Multiple Myeloma Symposium | Novel and Next Generation Therapy
Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее
2019 Multiple Myeloma Symposium | Cellular ImmunotherapyПодробнее
Myeloma Updates 2018: Best of ASCO/EHA/IMWGПодробнее
Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее
CAR-Ts: Next Generation Products and Strategies? Upfront, High Risk?Подробнее
Multiple Myeloma Symposium: Future of Treatment | Dana-Farber Cancer InstituteПодробнее
New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее
2019 Multiple Myeloma Symposium | Diagnosis, Prognosis & RiskПодробнее
What are new treatment options for newly-diagnosed multiple myeloma patients? Dr. Paul G. RichardsonПодробнее
2019 Multiple Myeloma Symposium | Current & Future TreatmentПодробнее
2019 Multiple Myeloma Symposium | Managing Bone DiseaseПодробнее
A Patient’s Perspective on Multiple Myeloma TreatmentПодробнее
2019 Multiple Myeloma Symposium | Smoldering Multiple MyelomaПодробнее
Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее
Future of Novel Next Generation Therapy in the Management of Relapsed/Refractory Multiple MyelomaПодробнее
Fueling Innovation in Multiple Myeloma: Thoughts From the ChairПодробнее
Reaching the Next Level of Myeloma Patient Care: Antibody Therapy and Novel Mechanisms of ActionПодробнее
2019 Multiple Myeloma Symposium | Q&A with Clifton Mo, MDПодробнее
Multiple Myeloma Symposium: A Patient's Perspective | Dana-Farber Cancer InstituteПодробнее
2019 Multiple Myeloma Symposium | Symptom ManagementПодробнее
